- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02013674
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study) (Trident)
A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.
Study Overview
Status
Intervention / Treatment
Detailed Description
Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI scheduled to undergo cardiac catheterization will be enrolled in the study.This is a phase II study intended to gain additional safety and efficacy assessments among two dose levels previously studied in a phase I setting. In this study, a 20 million total hMSC dose and a 100 million total hMSC dose will be randomly allocated administered via the Biocardia Helical infusion system in a blinded manner.
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional myocardium. Ideally, graft cells should be readily available, easy to culture to ensure adequate quantities for transplantation, and able to survive in host myocardium, which is often a hostile environment of limited blood supply and immunorejection. Whether effective cellular regenerative strategies require that administered cells differentiate into adult cardiomyocytes and couple electromechanically with the surrounding myocardium is increasingly controversial and recent evidence suggests that this may not be required for effective cardiac repair. Most importantly, transplantation of graft cells should improve cardiac function and prevent adverse ventricular remodeling. To date, a number of candidate cells have been transplanted in experimental models, including fetal and neonatal cardiomyocytes, embryonic stem cell-derived myocytes, tissue engineered contractile grafts9, skeletal myoblasts, several cell types derived from adult bone marrow, and cardiac precursors residing within the heart itself. There has been substantial clinical development in the use of whole bone marrow and skeletal myoblast preparations in studies enrolling both post-infarction patients and patients with chronic ischemic left ventricular dysfunction and heart failure. The effects of bone marrow-derived mesenchymal stem cells (MSCs) have also been studied clinically.
Currently, bone marrow or bone marrow-derived cells represent a highly promising modality for cardiac repair. The totality of evidence from trials investigating autologous whole bone marrow infusions into patients following myocardial infarction supports the safety of this approach. In terms of efficacy, increases in ejection fraction are reported in the majority of the trials.
Chronic ischemic left ventricular dysfunction is a common and problematic condition; definitive therapy in the form of heart transplantation is available to only a tiny minority of eligible patients. Cellular cardiomyoplasty for chronic heart failure has been studied less than for acute MI, but represents a potentially important alternative for this disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- ISCI / University of Miami
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to participate in this study, a patient MUST:
- Be ≥ 21 and < 90 years of age.
- Provide written informed consent.
- Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.
- Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensin-converting enzyme inhibition, the patient must have been on a stable dose of a clinically appropriate agent for 1 month.
- Be a candidate for cardiac catheterization within 5 to 10 weeks of screening as determined by doctors.
- Have an ejection fraction of less than or equal to 50% by gated blood pool scan, two-dimensional echocardiogram, CT, or left ventriculogram within the prior six months and not in the setting of a recent ischemic event.
Exclusion Criteria:
In order to participate in this study, a patient MUST NOT:
- Have a baseline glomerular filtration rate ≤ 35 ml/min/1.73m2.
- Have a known, serious radiographic contrast allergy.
- Have a Mechanical aortic valve or heart constrictive device.
- Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less).
- Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
- Require coronary artery revascularization. Patients who require or undergo revascularization procedures should undergo these procedures a minimum of 3 months in advance of treatment in this study. In addition, patients who develop a need for revascularization following enrollment will be submitted for this therapy without delay.
- Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (non-sustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or Corrected for heart rate (QTc) interval > 550 ms on screening ECG
- Automatic Implantable Cardioverter Defibrillator (AICD) firing in the past 60 days prior to enrollment.
- Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/µl or platelet values < 100,000/µl without another explanation.
- Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal (ULN).
- Have a coagulopathy = (INR > 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR < 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment
- Have known allergies to penicillin or streptomycin.
- Hypersensitivity to Dimethyl Sulfoxide (DMSO).
- Be an organ transplant recipient.
- Have a history of organ or cell transplant rejection
- Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.
- Have a non-cardiac condition that limits lifespan to < 1 year.
- Have a history of drug or alcohol abuse within the past 24 months.
- Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.
- Be serum positive for HIV, hepatitis BsAg or viremic hepatitis C.
- Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
- Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 20 million Allogeneic hMSCs
Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
|
Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
Other Names:
|
Experimental: Group 2: 100 million Allogeneic hMSCs
Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
|
Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Serious Adverse Events (SAE).
Time Frame: One month post-catheterization
|
Incidence (at one month post-catheterization) of any treatment-emergent serious adverse events, defined as the composite of: death, non-fatal MI, stroke, hospitalization for worsening heart failure, cardiac perforation, pericardial tamponade, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 15 seconds or with hemodynamic compromise).
|
One month post-catheterization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infarct Scar Size (ISS)
Time Frame: Baseline, 12 months
|
Determined by delayed contrast enhanced Computed Tomography (CT) Scan
|
Baseline, 12 months
|
Number of Participant With Reported Tissue Perfusion
Time Frame: 6 months, 12 months
|
Tissue perfusion measured by CT.
|
6 months, 12 months
|
Peak Oxygen Consumption (VO2)
Time Frame: Baseline, 6 months, 12 months
|
Peak VO2 assessed via treadmill determination.
|
Baseline, 6 months, 12 months
|
Six-minute Walk Test.
Time Frame: Baseline, 3 months, 6 months, 12 months
|
A test that measures how far a patient can walk in 6 minutes.
|
Baseline, 3 months, 6 months, 12 months
|
Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.
Time Frame: Baseline to 3 months, Baseline to 6 months, Baseline to 12 months
|
Changed in NYHA Functional Classification will be evaluated.
Worsened: Documented increase in limitation in physical activity.
Improved: Documented decrease in limitation in physical activity.
Unchanged: No documented change in limitation in physical activity.
|
Baseline to 3 months, Baseline to 6 months, Baseline to 12 months
|
Number of Incidents of Major Adverse Cardiac Events (MACE).
Time Frame: 1 month, 6 months, 12 months post injection.
|
Incidence of the Major Adverse Cardiac Events (MACE) endpoint, defined as the composite incidence of (1) death, (2) hospitalization for worsening heart failure, or (3) non-fatal recurrent MI.
|
1 month, 6 months, 12 months post injection.
|
Number of Participants With Treatment Emergent Adverse Event (AE)
Time Frame: 6 months, 12 months
|
Incidence of Treatment Emergent Adverse Event defined as any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of the study product.
|
6 months, 12 months
|
Minnesota Living With Heart Failure (MLHF) Questionnaire Scores
Time Frame: Baseline, 3 months, 6 months, 12 months
|
Minnesota Living with Heart Failure (MLHF) Questionnaire has a total score from 0 to 105.
A higher score indicates that participant's heart failure is preventing them from living their life.
|
Baseline, 3 months, 6 months, 12 months
|
Echocardiographic-derived Measures of Left Ventricular Function
Time Frame: 6 months, 12 months
|
Left ventricular end diastolic wall thickness as determined by echocardiogram.
|
6 months, 12 months
|
Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)
Time Frame: Baseline, 12 Months
|
As determined by Computed Tomography Scan
|
Baseline, 12 Months
|
Difference Between the Regional Left Ventricular Wall Thickening
Time Frame: Baseline, Month 12
|
As determined by Computed Tomography Scan
|
Baseline, Month 12
|
Difference Between Left Ventricular End Diastolic Wall Thickness
Time Frame: Baseline, 12 Months
|
As determined by Computed Tomography Scan
|
Baseline, 12 Months
|
Difference Between the Left Ventricular Ejection Fraction (LVEF)
Time Frame: Baseline, 12 months
|
Change in 1-year LVEF by CT as compared to baseline.
|
Baseline, 12 months
|
Difference in LVEF
Time Frame: Baseline, 6 months, 12 months
|
As assessed via ECHO
|
Baseline, 6 months, 12 months
|
Difference in Left Ventricular Volume
Time Frame: Baseline, 6 months, 12 months
|
Difference in left ventricular end diastolic and end systolic volume will be assessed via ECHO
|
Baseline, 6 months, 12 months
|
Difference in Left Ventricular Volume
Time Frame: Baseline, 12 months
|
Difference in left ventricular end diastolic and end systolic volume will be assessed via CT
|
Baseline, 12 months
|
Difference in Left Ventricular Regional Myocardial Perfusion
Time Frame: Baseline, 12 months
|
As measured via myocardial mass by CT
|
Baseline, 12 months
|
Number of Participants With Abnormal Electrocardiogram (ECG) Reads.
Time Frame: 12 months
|
The number of participants with abnormal ECG readings via 24 hour ambulatory ECG recordings as assessed per treating physician discretion.
|
12 months
|
Number of Clinically Significant of Abnormal Lab Values.
Time Frame: 12 months
|
Clinical significance of abnormal lab values will be assessed by treating physician
|
12 months
|
Serial Troponin I
Time Frame: 12 hours, 24 hours post cardiac catheterization
|
Serial Troponin I values in ng/mL over time.
|
12 hours, 24 hours post cardiac catheterization
|
Number of Participants With Abnormal ECHO Reading
Time Frame: 6 hours post cardiac catheterization
|
The number of participants with abnormal reading post-cardiac catheterization.
As assessed per treating physician discretion.
|
6 hours post cardiac catheterization
|
Creatinine Kinase Muscle/Brain (CK-MB)
Time Frame: 12 hours, 24 hours post cardiac catheterization
|
CK-MB values in ng/mL over time.
|
12 hours, 24 hours post cardiac catheterization
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20120660
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
Clinical Trials on Allogeneic hMSCs
-
Marilyn GlassbergThe Marcus FoundationTerminated
-
Joshua M HareWithdrawnCrohn's Disease | Stem Cells | Fistulizing Crohn's DiseaseUnited States
-
Marilyn GlassbergCompletedBronchiectasisUnited States
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedNon-ischemic Dilated CardiomyopathyUnited States
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
Longeveron Inc.TerminatedHypoplastic Left Heart SyndromeUnited States
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedDiabetes Mellitus, Type 2United States
-
National University of Ireland, Galway, IrelandUniversity Hospital of LimerickCompletedCritical Limb IschemiaIreland
-
Joshua M HareThe University of Texas Health Science Center, Houston; United States Department...RecruitingNon-ischemic Dilated CardiomyopathyUnited States
-
Joshua M HareTerminatedTreatment Resistant DepressionUnited States